List view / Grid view
15 February 2016 | By Victoria White
Researchers say drug discovery processes are becoming unsustainably expensive despite huge technological advances because the wrong methods are being used…
12 February 2016 | By DiscoverX Corporation
If you are looking to advance compounds to the clinic, BioMAP® phenotypic profiling services will predict the behaviour of your drug candidates in patients...
12 February 2016 | By DiscoverX Corporation
PathHunter® bioassays are cell-based assays that are highly validated, simple, and target specific to support biologics drug development...
9 February 2016 | By Dr Bissan Al-Lazikani and Elizabeth Coker, The Institute of Cancer Research, London
Dr Bissan Al-Lazikani and Elizabeth Coker discuss canSAR: the first public domain example of Big Data for drug discovery...
8 February 2016 | By SMi Group
SMi will open its doors to host RNA Therapeutics 2016 in just 1 week on 15th and 16th February in Central London...
8 February 2016 | By Victoria White
Biogen’s new membership follows the launch of the new CTTV Target Validation Platform, which helps researchers identify therapeutic targets for new medicines...
4 February 2016 | By Victoria White
Researchers showed that virus-like particles carrying LXY-30 could home in on breast cancer cells both in a laboratory dish and in a mouse model...
28 January 2016 | By Victoria White, Digital Content Producer, Drug Target Review
2015 was an exciting year for the drug discovery industry. Here we look at a selection of stories that particularly stood out for us…
28 January 2016 | By Victoria White
The ADDoPT project addresses the key challenge of getting new innovative medicines to market in the quickest and most cost-effective way...
27 January 2016 | By Victoria White
The study marks the first time researchers have replaced a defective gene associated with a sensory disease in stem cells that were derived from a patient's tissue...
26 January 2016 | By Victoria White
Scientists from UTSW have crafted synthetic "dendrimer" nanoparticles that are able to provide a tumour-suppressing effect without further damaging the liver or neighbouring tissue...
21 January 2016 | By Hans Fliri PhD, Chairman, Cypralis
Here, Dr Hans Fliri, Chairman and CEO of Selcia and Chairman of Cypralis, presents a strong case for targeting mitochondrial cyclophilin D to prevent progression of chronic neurodegenerative diseases...
21 January 2016 | By Victoria White
The Lead Discovery Centre (LDC) and Roche have announced that they are to collaborate to identify and leverage innovative therapeutic opportunities that address diseases of unmet medical need...
21 January 2016 | By Victoria White
The researchers have announced a major improvement in CRISPR-Cas9 technology that achieves an unprecedented success rate of 60% when replacing a short stretch of DNA with another...
20 January 2016 | By Victoria White
Through the Phenotypic Discovery Initiative (PDi), partners will build robust, disease-relevant phenotypic assays with a focus on human-derived systems with the aim of identifying new drug targets and hit molecules.
